The presence of DMI is a biomarker of poor vision in patients with diabetes[1,2,3] and adversely affects the visual outcomes of intravitreal injections of anti-vascular endothelial growth factors (VEGFs) for DME.[4] Progressive FAZ enlargement occurs at a rate of 5–10% of baseline FAZ area per year in eyes with established macular ischemia and could be considered a predictor of vision loss.[5]. Here, VEGFA is linked to diabetes mellitus.